share_log

Ginkgo Bioworks | 4: Statement of changes in beneficial ownership of securities-Officer Coen Steven P.

SEC announcement ·  Jun 6 05:12
Summary by Futu AI
Steven P. Coen, associated with Ginkgo Bioworks Holdings, Inc. (trading symbol DNA), completed a series of transactions involving the company's Class A Common Stock. On May 31, 2024, Coen acquired a total of 29,745 shares through the exercise or conversion of derivative securities, at no reported transaction price. Subsequently, on June 3, 2024, Coen sold 13,440 shares in an open market transaction at a price of $0.549 per share, totaling a market value of $7,378.56. After these transactions, Coen's direct holdings in Ginkgo Bioworks amounted to 178,832 shares of Class A Common Stock.
Steven P. Coen, associated with Ginkgo Bioworks Holdings, Inc. (trading symbol DNA), completed a series of transactions involving the company's Class A Common Stock. On May 31, 2024, Coen acquired a total of 29,745 shares through the exercise or conversion of derivative securities, at no reported transaction price. Subsequently, on June 3, 2024, Coen sold 13,440 shares in an open market transaction at a price of $0.549 per share, totaling a market value of $7,378.56. After these transactions, Coen's direct holdings in Ginkgo Bioworks amounted to 178,832 shares of Class A Common Stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.